CA2997051C - Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof - Google Patents

Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof Download PDF

Info

Publication number
CA2997051C
CA2997051C CA2997051A CA2997051A CA2997051C CA 2997051 C CA2997051 C CA 2997051C CA 2997051 A CA2997051 A CA 2997051A CA 2997051 A CA2997051 A CA 2997051A CA 2997051 C CA2997051 C CA 2997051C
Authority
CA
Canada
Prior art keywords
group
amino
pyrazolo
pyrimidine
acryloylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2997051A
Other languages
English (en)
French (fr)
Other versions
CA2997051A1 (en
Inventor
Yuichi Kawai
Hiroki Irie
Takeshi Sagara
Kazutaka Miyadera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CA2997051A1 publication Critical patent/CA2997051A1/en
Application granted granted Critical
Publication of CA2997051C publication Critical patent/CA2997051C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2997051A 2015-09-01 2016-08-31 Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof Active CA2997051C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015172354 2015-09-01
JP2015-172354 2015-09-01
PCT/JP2016/075380 WO2017038838A1 (ja) 2015-09-01 2016-08-31 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
CA2997051A1 CA2997051A1 (en) 2017-03-09
CA2997051C true CA2997051C (en) 2020-03-24

Family

ID=58188946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997051A Active CA2997051C (en) 2015-09-01 2016-08-31 Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof

Country Status (20)

Country Link
US (2) US9920060B2 (ja)
EP (1) EP3345907B1 (ja)
JP (1) JP6141568B1 (ja)
KR (1) KR102075886B1 (ja)
CN (1) CN108349981B (ja)
AU (1) AU2016317521B2 (ja)
BR (1) BR112018004175B8 (ja)
CA (1) CA2997051C (ja)
DK (1) DK3345907T3 (ja)
ES (1) ES2799520T3 (ja)
HK (1) HK1257146A1 (ja)
MX (1) MX2018002520A (ja)
MY (1) MY191938A (ja)
PH (1) PH12018500437A1 (ja)
PL (1) PL3345907T3 (ja)
PT (1) PT3345907T (ja)
RU (1) RU2705579C2 (ja)
SG (1) SG11201801365YA (ja)
TW (1) TWI659957B (ja)
WO (1) WO2017038838A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
PT3269370T (pt) * 2016-02-23 2020-03-05 Taiho Pharmaceutical Co Ltd Novo composto de pirimidina condensada ou sal do mesmo
MA47696A (fr) * 2017-02-28 2020-01-08 Taiho Pharmaceutical Co Ltd Activateur d'effet antitumoral utilisant un composé pyrazolo[3,4-d]pyrimidine
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN106967303A (zh) * 2017-05-02 2017-07-21 杭州福莱蒽特精细化工有限公司 一种艳色兰偶氮染料及其制备方法和应用
US20210332056A1 (en) * 2018-08-29 2021-10-28 Taiho Pharmaceutical Co., Ltd. Crystal of pyrazolo[3,4-d]pyrimidine
US20210252000A1 (en) * 2018-08-29 2021-08-19 Taiho Pharmaceutical Co., Ltd. THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
EP3909584B1 (en) * 2019-01-11 2023-12-13 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof
WO2021164697A1 (zh) * 2020-02-18 2021-08-26 深圳市塔吉瑞生物医药有限公司 取代的酰胺衍生物及其组合物及用途
CN111440138A (zh) * 2020-04-30 2020-07-24 中国林业科学研究院林产化学工业研究所 具有hdac抑制和抗肿瘤活性的新型漆酚基异羟肟酸衍生物的合成方法
MX2023000692A (es) * 2020-07-15 2023-02-13 Taiho Pharmaceutical Co Ltd Cristal de compuesto de pirimidina.
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co Ltd PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
CA3189460A1 (en) 2020-07-15 2022-01-20 Taiho Pharmaceutical Co., Ltd. Egfr inhibitor
IL301532A (en) 2020-09-23 2023-05-01 Scorpion Therapeutics Inc History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
JP2023545414A (ja) * 2020-10-05 2023-10-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｅｒ２の強力かつ選択的な阻害剤
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
AU2023212271A1 (en) * 2022-01-25 2024-07-25 KSQ Therapeutics, Inc. Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE403428T1 (de) * 2003-06-27 2008-08-15 Pfizer Prod Inc Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
WO2007067781A2 (en) 2005-12-08 2007-06-14 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2954900A1 (en) * 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP5974084B2 (ja) * 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
JP6035423B2 (ja) 2013-08-12 2016-11-30 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
ES2709509T3 (es) * 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2

Also Published As

Publication number Publication date
EP3345907A1 (en) 2018-07-11
CA2997051A1 (en) 2017-03-09
DK3345907T3 (da) 2020-06-22
BR112018004175B8 (pt) 2023-10-31
JP6141568B1 (ja) 2017-06-07
US20180201615A1 (en) 2018-07-19
EP3345907B1 (en) 2020-04-22
RU2018111439A3 (ja) 2019-10-02
RU2018111439A (ru) 2019-10-02
EP3345907A4 (en) 2019-03-20
MY191938A (en) 2022-07-19
JPWO2017038838A1 (ja) 2017-08-31
PH12018500437B1 (en) 2018-08-29
US9920060B2 (en) 2018-03-20
KR102075886B1 (ko) 2020-02-11
PH12018500437A1 (en) 2018-08-29
TWI659957B (zh) 2019-05-21
AU2016317521B2 (en) 2019-02-14
CN108349981B (zh) 2021-03-30
PL3345907T3 (pl) 2020-09-07
BR112018004175B1 (pt) 2023-07-25
US10329300B2 (en) 2019-06-25
WO2017038838A1 (ja) 2017-03-09
SG11201801365YA (en) 2018-03-28
MX2018002520A (es) 2019-02-07
US20170217970A1 (en) 2017-08-03
KR20180041757A (ko) 2018-04-24
HK1257146A1 (zh) 2019-10-11
PT3345907T (pt) 2020-06-23
BR112018004175A2 (ja) 2018-09-25
RU2705579C2 (ru) 2019-11-08
CN108349981A (zh) 2018-07-31
AU2016317521A1 (en) 2018-03-29
TW201718592A (zh) 2017-06-01
ES2799520T3 (es) 2020-12-18

Similar Documents

Publication Publication Date Title
CA2997051C (en) Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
US9580432B2 (en) Fused pyrimidine compound or salt thereof
TW202115065A (zh) Kras突變蛋白抑制劑
JP2018530539A (ja) スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
KR20140059164A (ko) 트라이사이클릭 자이라제 억제제
WO2019228404A1 (zh) 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
CN108727343A (zh) 含有3-氨基四氢吡咯的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
US11696917B2 (en) Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound
EP3851108B1 (en) Borate-based drug and use thereof
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
WO2021114691A1 (zh) 含氮并环化合物、其制备方法及用途
CA2478276A1 (en) Azepane derivatives and their use as atk1 inhibitors
RU2799006C2 (ru) СРЕДСТВО, УСИЛИВАЮЩЕЕ ПРОТИВООПУХОЛЕВОЕ ДЕЙСТВИЕ С ПРИМЕНЕНИЕМ СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-d]ПИРИМИДИНА
EP4317143A1 (en) Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180228